While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.
By Ifham Nizam After years of delays caused by financial struggles, political instability and a global pandemic, the much-anticipated Karapitiya Trail Cancer Hospital is finally back on track. The ...
Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.